Could Cosmos Holdings (COSM) Become a Major Disruptor in an Estimated $1.3 Trillion Global Pharma Industry

The health scare has only accelerated the global demand for medication. In fact, according to Fortune Business Insights, in 2020, the health scare “accelerated the demand for effective treatments and drugs worldwide” and caused the global pharmaceutical industry to reach an estimated valuation of $1.3 Trillion. (2)

In addition, they noted there’s an “increasing prevalence of chronic disease and the growing adoption of modern technologies that are leading to the evolving pharmaceuticals sector.” (3) This is why Fortune believes we could see the global pharmaceuticals market size reach nearly $2.15 trillion by 2027 at an estimated CAGR of 7.0%.(3)

One of the top companies benefiting from this pharma rush is Cosmos Holdings (NASDAQ:COSM). Cosmos is a disruptive company that offers customers and shareholders diversified exposure to several in-demand and growing verticals in the pharma and wellness space, including (4): Branded Pharmaceuticals, Generic Pharmaceuticals, Health Products & Food Supplements, Research & Development, Acquisitions, Green leaf derived products, Local & Direct to Pharmacy Wholesale

Clearly, Cosmos and its unique business model may be doing something right. Not only did Cosmos see 2020 revenue growth of about 40% and jaw-dropping gross profit growth of nearly 120%, (9) it reported 15.8% year-over-year growth and a 27.8% sequential increase in revenue for Q2 2021.(1)

But that’s not the company’s biggest news at the moment…In a major company milestone, Cosmos just up listed to the Nasdaq Capital Market (10)

Click HERE to Read 7 Top Reasons To Get Cosmos Holdings On Your Radar Now

Other companies in Cosmos Holdings’s space includes: AmerisourceBergen (NYSE:ABC), McKesson (NYSE:MCK), Henry Schein (NASDAQ:HSIC), Patterson Companies (NASDAQ:PDCO) and PetIQ (NASDAQ:PETQ).


Source 1:,

Source 2:,

Source 3:,

Source 4:,

Source 9:,

Source 10: